The paper concluded that the combination therapy of ACT with TIL using anti-4-1BB with anti-PD-1 therapy was a safe and feasible treatment, offering a potential treatment for metastatic melanoma [104]. The gene discussed is PDCD1; the disease is metastatic melanoma.